Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Short Title: EA5162

Enrollment Status: Recruiting

NCT #: NCT03191149

Specialty Area: Oncology

Condition Studied: Advanced or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Age Groups: Adult; Older Adult

Phase: II

Study Information

Summary / Purpose

To find out how well osimertinib works in treating non-small cell lung cancer with an EGFR exon 20 mutation that is advanced or has come back after earlier treatment.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) with an EGFR exon 20 insertion mutation
Cancer may be newly diagnosed or has come back after treatment

What's Involved

Participation in the study will include:

Treatment with osimertinib (a targeted therapy) given orally
CT scans, MRI, echocardiograms, and MUGA scans to monitor response to treatment and side effects
Blood and tissue samples collected
Questionnaires

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT03191149

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews